.png)
Author
The author is Deputy Chief Executive Officer of Biocon Biologics, with 25 years of leadership experience in operational and strategic roles and has led large, diverse teams at R&D, Manufacturing and Projects & Engineering during his tenure at Biocon.
With originator biologics worth over USD 70 billion scheduled to lose patent exclusivity over the next five years, biosimilars present a large and important opportunity for the global pharma industry in general and India in particular
Read More
